Evidence map›Paper›PMID 40736861›Full record

ArticleAdvances in experimental medicine and biology2025

"Seeing Stars": The Gene Therapy Revolution.

Gareth D Mercer, Brian G Ballios, Peter J Kertes

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gareth D MercerDepartment of Ophthalmology & Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Brian G BalliosDepartment of Ophthalmology & Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Peter J KertesDepartment of Ophthalmology & Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. peter.kertes@sunnybrook.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy is the delivery of exogenous DNA for the treatment of human disease (Friedmann and Roblin 1972). The advantage of gene therapy over other treatments for IRDs is the potentially curative effect of replacing, repairing, or silencing the responsible gene defect. The European Medicines Agency and the American Food and Drug Administration (FDA) approved the first gene therapy products in 2012 and 2017, respectively. Among them was voretigene neparvovec-rzyl (Luxturna), a revolutionary step in the treatment of IRDs.

Indexed as

Genetic TherapyAnimalsGenetic VectorsHumans

Identifiers

PMID40736861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.